Aimovig® (erenumab) has received a positive opinion from the CHMP for migraine, steering the way towards a marketing authorization from the EMA.
Clinical trial announcements, orphan-drug designation and more: check out our round-up of the biggest news from the neuroscience and neurology industries this week.
A study at University Hospital Mannheim and Heidelberg University has indicated that migraine sufferers have significantly higher concentrations of sodium present in their cerebrospinal fluid than non-sufferers.
Data from a head-to-head, open-label study were presented at the 18th Congress of the International Headache Society in Vancouver (Canada, 7–10 September 2017).
Research presented at the Congress of the European Academy of Neurology 2017 confirms that cannabinoids are as suitable for preventing migraine attacks as other pharmaceutical treatments.
A new study has indicated that a wireless patch on the arm that provides electrical stimulation could be as effective in reducing migraine pain as conventional drugs.
In this editorial, the authors discuss the building body of evidence for the role of cortical spreading depression in migraine headache, as well as the further investigation required into this relationship.
We will describe the pharmacokinetic profile, clinical efficacy and safety data of the sumatriptan iontophoretic…
This editorial discusses the use of botulinum neurotoxin A in preventing headaches in adult patients with chronic migraine.